The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, healthy aging, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
August 2023 Lauren McGivern,
Although it will not fully solve patent barriers to the access of medicines, implementation of compulsory licensing (and specifically those for the import and export of pharmaceutical products) will provide governments with another tool to safeguard their population’s public health. More
August 2023 Peter J. Neumann, Elliott Crummer, James D. Chambers, Sean R. Tunis,
Context: The Food and Drug Administration (FDA)’s accelerated-approval pathway expedites patient access to promising treatments. However,… More
April 2023 Dalton Conley,
Since before Ponce de Leon’s quest for the fountain of youth that led him to discover what is now Florida and Cervantes’ Don Quixote’s likeminded search, humans have sought a way to slow or even reverse the aging process. Now, however, we have preliminary evidence that there are indeed methods of slowing down senescence. More
January 2023 Sanket S. Dhruva, Marcus A. Bachhuber, Ashwin Shetty, Hayden Guidry, Vinay Guduguntla, Rita F. Redberg,
Ideally, medical care is based on diagnostics and treatments for health conditions that have evidence that their benefits outweigh any potential… More
May 2022 Huseyin Naci, Ilias Kyriopoulos, William B. Feldman, Thomas J. Hwang, Aaron S. Kesselheim, Amitabh Chandra,
This study finds that newly approved drugs are frequently subject to formulary exclusions and restrictions such as prior authorization in Medicare Part D plans. More
March 2022 Julie Donohue, PhD,
In 1993, Stephen Soumerai and coauthors published “A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of… More
March 2022 Lindor Qunaj, Anna Kaltenboeck, Peter B. Bach,
This study by Lindor Qunaj of Montefiore Medical Center and colleagues finds that compulsory licensing, a practice whereby national authorities can enable the production of a generic before the original patent expires, is rarely used to address drug prices and, when used, is unlikely to contribute to price discounts. More
August 2021 Liam Bendicksen, Benjamin N. Rome, Jerry Avorn, Aaron S. Kesselheim,
Context: Rising prescription drug costs are consuming a growing proportion of state and private budgets. In response, lawmakers have experimented with… More
June 2021 Richard G. Frank, Thomas G. McGuire, Ian Nason,
Context: The image of generic drugs as a commodity sold in competitive markets is an oversimplification, as evidenced by increasing accounts of price… More
April 2021 George Maliha, Sara Gerke, I. Glenn Cohen, Ravi B. Parikh,
After more than a decade of promise and hype, artificial intelligence (AI) and machine learning (ML) are finally making inroads into clinical… More
Get the Latest from the Milbank Memorial Fund
The Milbank Quarterly’s multidisciplinary approach and commitment to applying the best empirical research to practical policymaking offers in-depth assessments of the social, economic, political, historical, legal, and ethical dimensions of health and health care policy.